This presentation, delivered at the WHO Product Development for Vaccines Advisory Committee (PD-VAC) meeting, 7-9 September 2015, provides an update from the Meningitis Vaccine Project (MVP), a collaboration between the WHO and PATH dedicated to eliminating epidemic meningitis in sub-Saharan Africa. It covers the introduction and rollout in 26 countries of MenAfriVac, a vaccine developed by the project to protect infants of less than a year to people up to 29 years of age in the African meningitis belt against meningococcal bacterium Neisseria meningitidis group A.